Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2011

View Archived Issues

PCI-27483/gemcitabine combination is safe in advanced/metastatic pancreatic cancer

French scientists describe novel piperidine derivatives

Cancer-targeting nanoparticle-size Cornell dots to enter first-in-human trial

Bharat Biotech initiates phase III trial of thrombolytic agent THR-100 in India

Bryostatin 1 prevents synapse loss in vivo, improving symptoms of AD

Preclinical findings support role of N-acetylcysteine in TTP therapy

Armed oncolytic virus OBP-702 active against osteosarcoma cells

New drug discovery strategy creates synthetic analogues based on natural products

Derma Sciences reports phase II data on DSC-127 in diabetes-related foot ulcers

Kythera Biopharma reports phase IIb data on ATX-101

Galapagos and Merck & Co. agree to end strategic alliances

CardioVascular BioTherapeutics files for FDA fast track status for CVBT-141B

Tacere Therapeutics achieves milestone under collaboration with Pfizer

FDA sets new PDUFA date for AstraZeneca's Brilinta

Ceregene advances phase IIb CERE-120 trial in Parkinson's disease

Natural marine product largazole has osteogenic potential

Paclitaxel shows promise as treatment of spinal cord injury

FluEnz approved in E.U. for prevention of seasonal flu in children

SHELTER trial data reported on resminostat in sorafenib-resistant hepatocellular carcinoma

Lilly and JDRF to study beta-cell regeneration to treat type 1 diabetes

Anacor Pharma begins phase IIb trial of AN-2728 in psoriasis

AstraZeneca discontinues ENTHUSE Study 15 of zibotentan in prostate cancer

Aveo's anticancer antibody AV-299 to be called ficlatuzumab

Phase IIb trial of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy meets primary endpoint

FDA removes clinical hold on Icagen's IND for epilepsy candidate ICA-10566

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...